Trial Profile
Randomized Crossover Trial to Assess the Effects and Quality of Life in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel: QOLINPAC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms QOLINPAC
- 10 Jul 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2019.
- 23 Oct 2018 QOL analyses and translational studies will be presented at the congress, as reported in an abstract presented at the 43rd European Society for Medical Oncology Congress
- 20 Jul 2018 Status changed from active, no longer recruiting to completed.